Harness Therapeutics is making significant strides in the battle against Huntington’s disease (HD) by nominating HRN001 as its lead drug candidate. This initiative includes the formation of a distinguished clinical advisory board dedicated to guiding the program toward clinical evaluation.
Understanding Huntington’s Disease
Huntington’s disease is a hereditary neurodegenerative condition characterized by progressive cognitive, psychiatric, and motor deterioration. The onset of symptoms typically leads to a decline in quality of life, with many patients succumbing within 15 years. Despite advancements in our understanding of HD’s biological mechanisms, effective disease-modifying treatments remain elusive.
The Genetic Basis of HD
At the genetic level, HD is primarily caused by the expansion of CAG repeats within the huntingtin (HTT) gene. Recent research has highlighted the ongoing somatic expansion of these repeats as a pivotal factor in the disease’s onset and progression. Among potential therapeutic targets, FAN1 nuclease stands out due to its strong genetic correlation with disease onset, as indicated by genome-wide association studies.
Introducing HRN001
HRN001 is a novel antisense oligonucleotide specifically designed to target FAN1, aiming to enhance the expression of this essential DNA repair enzyme. By utilizing Harness’ proprietary MISBA® (microRNA site blocking ASO) platform, HRN001 facilitates targeted upregulation of protein levels, significantly minimizing the risk of overexpression.
Preclinical Successes
In preclinical studies, HRN001 has shown promising results, including robust FAN1 upregulation and a reduction in somatic expansion in HD models. Additionally, it has exhibited favorable pharmacokinetics and tolerability. The preclinical development phase will extend through 2026, with clinical trials anticipated to begin in 2027. Harness is also investigating the MISBA® platform’s potential applications in other triplet repeat disorders and various neurodegenerative diseases.
Building a Strong Advisory Board
To propel HRN001 toward clinical application, Harness has assembled a clinical advisory board (CAB) featuring prominent experts in Huntington’s disease research. The CAB includes:
- Dr. Irina Antonijevic (Chair) – Chief Medical Officer, Trace Neuroscience
- Dr. Anne Rosser – Professor of Clinical Neuroscience, Cardiff University
- Dr. Jeffrey Long – Professor of Psychiatry and Biostatistics, University of Iowa Health Care
- Dr. Ralf Reilmann – Founding Director and CEO, George-Huntington-Institute
- Dr. Roger Barker – Professor of Clinical Neuroscience, University of Cambridge
- Dr. Sarah Tabrizi – Professor of Clinical Neurology, University College London
- Dr. William Gray – Professor of Functional Neurosurgery, Cardiff University
This board will provide essential strategic guidance on clinical development, trial design, and translational strategies as the project progresses.
Presenting at Key Conferences
Dr. Andy Billinton, the Chief Scientific Officer of Harness Therapeutics, is set to present the company’s advancements at an upcoming conference in California from February 23-26. This presentation will offer further insights into the scientific rationale and development trajectory of HRN001.
A Commitment to the Huntington’s Disease Community
Dr. Jan Thirkettle, CEO of Harness Therapeutics, emphasized the importance of HRN001, stating that its nomination marks a significant milestone for the company. By precisely upregulating FAN1, which has compelling genetic validation for delaying disease onset, HRN001 represents a pioneering therapeutic approach to combating somatic expansion, a critical aspect of disease progression.
Collaborating with Experts
The establishment of the Clinical Advisory Board reflects Harness’ commitment to collaborating with leading figures in neurodegeneration and RNA biology. The company has gained support from notable life science investors, including foundational entities like Takeda Ventures and the Dementia Discovery Fund from SV Health Investors, as well as Epidarex Capital and Ono Ventures Investment.
Future Directions
Harness Therapeutics is dedicated to advancing HRN001 and exploring the broader implications of the MISBA® platform. The ongoing commitment to research and development signifies hope for patients and families affected by Huntington’s disease.
In conclusion, the innovations presented by Harness Therapeutics herald a new era in the quest for effective treatments for Huntington’s disease. With a strong scientific foundation and expert guidance, there is optimism for developing therapies that could significantly alter the course of this devastating condition.
- HRN001 targets FAN1 to combat somatic expansion in Huntington’s disease.
- The Clinical Advisory Board includes leading experts in the field.
- Preclinical studies show promising results, with clinical trials expected in 2027.
- Harness aims to expand the MISBA® platform to other neurodegenerative disorders.
Read more → www.businessweekly.co.uk